Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose atovaquone for prevention of Pneumocystis pneumonia in rheumatic disease patients on corticosteroids
jRCTs031210557Phase 2Completed
- Sponsor
- Chiba University Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atovaquone in pneumocystis pneumonia (PCP), rheumatism and collagenosis, sponsored by Chiba University Hospital. Primary endpoint: Incidence rate of Pneumocystis pneumonia in the first six months of the study. Started Mar 2022; status: completed.
02
Drugs
atovaquone
03
Conditions
pneumocystis pneumonia (PCP)rheumatismcollagenosis
Beyond the preview
Go deeper on jRCTs031210557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210557.